Genfit S.A. (GNFTF)
USD 5.55
(0.0%)
USD 5.55
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 54.8 Million EUR | 0.72% |
| 2022 | 54.99 Million USD | -3.47% |
| 2021 | 56.96 Million USD | -43.91% |
| 2020 | 101.57 Million USD | -5.56% |
| 2019 | 107.54 Million USD | 24.53% |
| 2018 | 86.36 Million USD | 15.98% |
| 2017 | 74.46 Million USD | 78.44% |
| 2016 | 41.72 Million USD | 78.43% |
| 2015 | 23.38 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 FY | 55.38 Million EUR | 0.72% |
| 2023 Q2 | 34.38 Million USD | 88.7% |
| 2023 Q1 | 18.22 Million EUR | -34.61% |
| 2023 Q3 | 13.99 Million EUR | -59.29% |
| 2023 Q4 | 29.27 Million EUR | 109.1% |
| 2022 Q4 | 27.86 Million USD | 123.2% |
| 2022 Q3 | 12.48 Million EUR | -50.74% |
| 2022 Q2 | 25.34 Million USD | 0.0% |
| 2022 FY | 54.99 Million USD | -3.47% |
| 2021 Q2 | 35.54 Million USD | 0.0% |
| 2021 FY | 56.96 Million USD | -43.91% |
| 2021 Q4 | 22.89 Million USD | 0.0% |
| 2020 Q2 | 59.34 Million USD | 0.0% |
| 2020 FY | 101.57 Million USD | -5.56% |
| 2020 Q4 | 36.34 Million USD | 0.0% |
| 2019 FY | 107.54 Million USD | 24.53% |
| 2019 Q2 | 54.69 Million USD | 0.0% |
| 2019 Q4 | 43.79 Million USD | 0.0% |
| 2018 FY | 86.36 Million USD | 15.98% |
| 2017 FY | 74.46 Million USD | 78.44% |
| 2016 FY | 41.72 Million USD | 78.43% |
| 2015 FY | 23.38 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 36.851% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -1014.375% |
| SQZ Biotechnologies Company | 85.61 Million USD | 35.991% |
| Evofem Biosciences, Inc. | 29.55 Million USD | -85.443% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | -47.102% |
| Mesoblast Limited | 5.9 Million USD | -828.567% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -3548.98% |
| Genus plc | 147.7 Million USD | 62.895% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -524.246% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -3985.141% |
| Marizyme, Inc. | 19.23 Million USD | -184.847% |
| ContraFect Corporation | 56.88 Million USD | 3.665% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -557.201% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -1143.095% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -3606.098% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -1779.272% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -1864.05% |
| MultiCell Technologies, Inc. | 567.42 USD | -9658354.055% |
| Accustem Sciences Inc. | 3.74 Million USD | -1362.837% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 36.234% |
| EV Biologics, Inc. | 531.96 Thousand USD | -10202.24% |
| Q BioMed Inc. | 3.43 Million USD | -1494.703% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | -121.744% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -13967.963% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -1985.768% |
| Biomind Labs Inc. | 994.18 Thousand USD | -5412.472% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 225.49 Million USD | 75.696% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -715.777% |
| Skye Bioscience, Inc. | 13.54 Million USD | -304.531% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -2575.056% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 219316.0% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -986.94% |
| IMV Inc. | 37.7 Million USD | -45.333% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -242.306% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -2886.439% |
| GB Sciences, Inc. | 1.42 Million USD | -3758.054% |
| Alpha Cognition Inc. | 9.7 Million USD | -464.664% |
| HST Global, Inc. | 140.9 Thousand USD | -38793.738% |
| CSL Limited | 3.44 Billion USD | 98.411% |
| Halberd Corporation | 74.84 Thousand USD | -73126.263% |
| Enzolytics Inc. | 2.17 Million USD | -2414.514% |
| Resverlogix Corp. | 12.71 Million USD | -331.12% |
| Affymax, Inc. | 39.38 Million USD | -39.146% |
| SYBLEU INC | 160.87 Thousand USD | -33965.989% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -1401.189% |
| argenx SE | 1.53 Billion USD | 96.426% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 4.589% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -5149.425% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -3370.024% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -1509.525% |
| AVAX Technologies, Inc. | 7.31 Million USD | -649.686% |
| Zenith Capital Corp. | 8.94 Million USD | -512.814% |
| Genscript Biotech Corporation | 825.34 Million USD | 93.36% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -314485.845% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -2132.054% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -31854.008% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 44.826% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -3014.433% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 1.97 Million USD | -2679.06% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -2839.545% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -404.316% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -2753.029% |
| BioStem Technologies, Inc. | 22.97 Million USD | -138.54% |
| ONE Bio Corp. | 6.44 Million USD | -750.48% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -30097.537% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -4003.844% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -4771.856% |
| Agentix Corp. | 1.37 Million USD | -3895.171% |
| LadRx Corporation | 3.81 Million USD | -1337.749% |
| Cell Source, Inc. | 4.32 Million USD | -1167.043% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -13090.558% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -5834.316% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -5834.316% |
| NovAccess Global Inc. | 2.46 Million USD | -2121.699% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -2178.815% |
| Itoco Inc. | 919.14 Thousand USD | -5862.511% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -1193.031% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -4797.587% |
| Kadimastem Ltd | 2.41 Million USD | -2173.919% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -20839.456% |
| CytoDyn Inc. | 18.05 Million USD | -203.489% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -217644.05% |
| Mobile Lads Corp. | 554.54 Thousand USD | -9782.679% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -24802.08% |
| Qrons Inc. | 643.67 Thousand USD | -8414.208% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -3760.002% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | -2357.712% |
| Rebus Holdings, Inc. | 664 Thousand USD | -8153.614% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -2917.31% |
| International Stem Cell Corporation | 5.27 Million USD | -939.727% |
| Bioxytran, Inc. | 3.82 Million USD | -1334.604% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -104006.987% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -269299.794% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | -51.117% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -3287.145% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -7347.865% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -1661.62% |
| Neutra Corp. | 243.82 Thousand USD | -22377.145% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -213.937% |
| PureTech Health plc | 144.59 Million USD | 62.099% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -167.469% |
| IXICO plc | 4.7 Million USD | -1064.308% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -522.985% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 53.457% |
| CSL Limited | 3.89 Billion USD | 98.592% |
| Cellectis S.A. | 97.32 Million USD | 43.687% |